221 related articles for article (PubMed ID: 28116467)
1. Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice.
Collins L; Sathiananthamoorthy S; Fader M; Malone-Lee J
Int Urogynecol J; 2017 Sep; 28(9):1351-1356. PubMed ID: 28116467
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder.
Abrar M; Stroman L; Malde S; Solomon E; Sahai A
Urology; 2020 Jan; 135():32-37. PubMed ID: 31626856
[TBL] [Abstract][Full Text] [Related]
3. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity.
Faure Walker NA; Syed O; Malde S; Taylor C; Sahai A
Urology; 2019 Jan; 123():242-246. PubMed ID: 30266377
[TBL] [Abstract][Full Text] [Related]
4. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
[TBL] [Abstract][Full Text] [Related]
6. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
Kennelly M; Green L; Alvandi N; Wehbe S; Smith JJ; MacDiarmid S; Mangel J; Schwartz M; Aboushwareb T; Murray B
Curr Med Res Opin; 2018 Oct; 34(10):1771-1776. PubMed ID: 29458265
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
8. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
Dowson C; Watkins J; Khan MS; Dasgupta P; Sahai A
Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
[TBL] [Abstract][Full Text] [Related]
9. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention.
Ghalayini IF; Al-Ghazo MA; Pickard RS
BJU Int; 2005 Jul; 96(1):93-7. PubMed ID: 15963128
[TBL] [Abstract][Full Text] [Related]
11. Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
Rahnama'i MS; Marcelissen TAT; Brierley B; Schurch B; de Vries P
Neurourol Urodyn; 2017 Sep; 36(7):1855-1859. PubMed ID: 28084637
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
13. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
14. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review.
Abrar M; Pindoria N; Malde S; Chancellor M; DeRidder D; Sahai A
Eur Urol Focus; 2021 Nov; 7(6):1448-1467. PubMed ID: 32616412
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
17. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
[TBL] [Abstract][Full Text] [Related]
18. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Mohee A; Khan A; Harris N; Eardley I
BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
[TBL] [Abstract][Full Text] [Related]
20. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.
Christiansen FE; Pedersen TB; Juel J; Kirkeby HJ
Scand J Urol; 2017 Oct; 51(5):392-396. PubMed ID: 28699369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
